Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

99/The impact of COVID-19 on amiodarone use in Nottingham University Hospitals DC cardioversion service

F Doleman (Presenting Author) – Nottingham University Hospitals, Nottingham; J Teoh – Nottingham University Hospitals, Nottingham; B Doleman – University Hospitals of Derby & Burton, Derby; T Robinson – Nottingham University Hospitals, Nottingham
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr99
Select a Section…
1

Article

Background: DC cardioversion (DCCV) is commonly used to restore sinus rhythm (SR) in patients with persistent atrial fibrillation or flutter (AF). DCCV is not always successful and often AF recurs soon after. Oral amiodarone therapy increases the efficacy of DCCV on the day and increases duration of SR after DCCV.

The NUH elective DCCV service was suspended for 6 months at the start of the COVID-19 pandemic. On its resumption, the NUH Arrhythmia team advised that all eligible patients be commenced on oral amiodarone at the time of referral for DCCV with the aims of achieving chemical cardioversion prior to DCCV, increasing on-the-day DCCV success rates, reducing the volume of repeat DCCVs and reducing the number of patients on the waiting list.

Methods: This was a retrospective analysis of 576 DCCV referrals and outcomes from January 2019 until August 2021; 281 prior to March 2020 and 295 after August 2020. Patient demographics, specialty of consultant in charge of patient care, body mass index, left ventricular function, left atrium size, medications, chemical cardioversion rates and DCCV success rates were collected. Propensity score matching to assess impact of amiodarone use was performed.

Results: Post COVID-19 suspension, 46% of DCCV patients were on amiodarone vs 33% before (p=0.001). Amiodarone use was higher in patients referred by an electrophysiology consultant (OR 1.42; 95% CI 1.01–1.98; p=0.04). Propensity score matching demonstrated that patients on amiodarone were more likely to chemically cardiovert and obviate the need for DCCV (OR 1.75, 95% CI 1.06–2.89; p=0.03). Being on amiodarone made no significant difference to on-the-day DCCV success (on amiodarone 155/170 [91%] vs off amiodarone 267/279 [95.7%]; p=ns).

Conclusion: Amiodarone use increased in DCCV patients post COVID-19, resulting in greater chemical cardioversion success and therefore reduced need for DCCV. Patients looked after by an electrophysiologist were more likely to receive amiodarone. Further follow-up is needed to assess maintenance of SR at first follow-up post DCCV.

2

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup